Academic literature on the topic 'Privileged structure'
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Privileged structure.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Journal articles on the topic "Privileged structure"
Shah, Dhruvin R., Rahul P. Modh, and Kishor H. Chikhalia. "Privileged s-triazines: structure and pharmacological applications." Future Medicinal Chemistry 6, no. 4 (March 2014): 463–77. http://dx.doi.org/10.4155/fmc.13.212.
Full textZhuang, Chunlin, Wen Zhang, Chunquan Sheng, Wannian Zhang, Chengguo Xing, and Zhenyuan Miao. "Chalcone: A Privileged Structure in Medicinal Chemistry." Chemical Reviews 117, no. 12 (May 10, 2017): 7762–810. http://dx.doi.org/10.1021/acs.chemrev.7b00020.
Full textSun, De-Juan, Ling-Juan Zhu, Yu-Qian Zhao, Yong-Qi Zhen, Lan Zhang, Cong-Cong Lin, and Li-Xia Chen. "Diarylheptanoid: A privileged structure in drug discovery." Fitoterapia 142 (April 2020): 104490. http://dx.doi.org/10.1016/j.fitote.2020.104490.
Full textLi, Z., P. Zhan, and X. Liu. "1,3,4-Oxadiazole: A Privileged Structure in Antiviral Agents." Mini-Reviews in Medicinal Chemistry 11, no. 13 (November 1, 2011): 1130–42. http://dx.doi.org/10.2174/138955711797655407.
Full textGaruti, Laura, Marinella Roberti, Giovanni Bottegoni, and Mariarosaria Ferraro. "Diaryl Urea: A Privileged Structure in Anticancer Agents." Current Medicinal Chemistry 23, no. 15 (May 19, 2016): 1528–48. http://dx.doi.org/10.2174/0929867323666160411142532.
Full textMcNaughton, Donald, Dennis Wachsmuth, Peter Kraus, Sven Herbers, Juan Wang, and Jens‐Uwe Grabow. "Determination of the “Privileged Structure” of 8‐Hydroxyquinoline." ChemPhysChem 22, no. 16 (July 7, 2021): 1692–97. http://dx.doi.org/10.1002/cphc.202100384.
Full textFerreira Pimentel, Luiz Claudio, Anna Claudia Cunha, Lucas Villas Boas Hoelz, Henayle Fernandes Canzian, Debora Inacio Leite Firmino Marinho, Nubia Boechat, and Monica Macedo Bastos. "Phenylamino-pyrimidine (PAP) Privileged Structure: Synthesis and Medicinal Applications." Current Topics in Medicinal Chemistry 20, no. 3 (March 18, 2020): 227–43. http://dx.doi.org/10.2174/1568026620666200124094949.
Full textHanley, Caroline. "Privileged Places: Race, Residence, and the Structure of Opportunity." Contemporary Sociology: A Journal of Reviews 36, no. 4 (July 2007): 335–37. http://dx.doi.org/10.1177/009430610703600411.
Full textMartín-Acosta, Pedro, Rosalyn Peña, Gabriela Feresin, Alejandro Tapia, Isabel Lorenzo-Castrillejo, Félix Machín, Ángel Amesty, and Ana Estévez-Braun. "Efficient Multicomponent Synthesis of Diverse Antibacterial Embelin-Privileged Structure Conjugates." Molecules 25, no. 14 (July 20, 2020): 3290. http://dx.doi.org/10.3390/molecules25143290.
Full textBielby, William T. "Minority Vulnerability in Privileged Occupations." ANNALS of the American Academy of Political and Social Science 639, no. 1 (December 15, 2011): 13–32. http://dx.doi.org/10.1177/0002716211422338.
Full textDissertations / Theses on the topic "Privileged structure"
Ravn, Jacob. "Development of privileged structure based libraries /." Måløv ; Cph. : Medicinal Chemistry Research III, Novo Nordisk A/S og Department of Medicinal Chemistry : The Danish University of Pharmaceutical Sciences, 2004. http://www.dfh.dk/phd/defences/jacobravn.htm.
Full textBuck, Michel. "A privileged quantum state from causal structure." Thesis, Imperial College London, 2014. http://hdl.handle.net/10044/1/24574.
Full textAnnadurai, Sivakumar. "Lead generation using a privileged structure-based approach." Diss., Temple University Libraries, 2011. http://cdm16002.contentdm.oclc.org/cdm/ref/collection/p245801coll10/id/213119.
Full textPh.D.
In drug discovery there are several approaches to lead generation and one traditional approach involves the synthesis and screening of a structurally diverse compound library against a number of biological targets to identify high affinity lead compounds. The use of a `privileged' structure-based compound library represents a viable approach that could lead to drug like lead compounds. Privileged structures are defined as those ligand substructures that may be used to generate high affinity leads for more than one type of receptor. Examples of privileged structures include phenyl substituted monocycles such as biphenyls, diphenyl methane derivatives, 1,4-dihydropyridines, fused ring systems such as chromones, quinoxalines, quinazolines, 2-benzoxazolones, indoles, benzimidazoles and benzofurans. There are several instances in the literature describing the development of compound libraries based on privileged structures with reportedly high hit rates. Privileged structure based approaches has been used with notable success in the identification of high affinity ligands especially for G-protein coupled receptors (GPCRs). The scaffold 2-aminothiazole (fused and non-fused) may be considered a privileged structure because of its occurrence in a wide variety of pharmaceuticals. The scaffold is found in antibacterials, anti-inflammatory agents, glutamate transporter (GLT-1) modulators, serotonin and muscarinic ligands. The present study involves the synthesis of a 2-aminothiazole (fused and non-fused) based compound library (60 compounds) by incorporating bioactive fragments shown to produce hits in the biological targets of interest. Microwave assisted organic synthesis (MAOS) has been employed at key steps of scaffold synthesis as well as in Suzuki coupling to generate the target aminothiazoles. Preliminary biological screening has resulted in the identification of some promising lead compounds. Trifluoromethoxy substituted aminothiazoles were found to be potent antimicrobials with MIC values in the range of 4-16 microgram/ml. Furanone based aminothiazoles showed affinity for muscarinic receptors. Piperidine based aminothiazoles showed greater than 90% of control (8-OH-DPAT) specific agonist response at the 5-HT1A receptor subtype. The Clog P values of the most potent antimicrobials were found to be in the range of 4.5-6.2 indicating the high lipophilicity of the compounds. High lipophilicity is known to cause solubility issues that may hamper future development. Therefore in an effort to make compounds with intermediate lipophilicity, the phenyl core of the potent aminothiazoles will be replaced with pyridine core using literature procedures (Pyridine core containing aminothiazoles showed Clog P < 4). Future plans include expanding the library, improving the yields of compounds and to evaluate the compounds as modulators of glutamate transporter (GLT-1). The work could be extended to include other privileged structures such as 2-aminooxazole, 2-aminobenzoxazole, 2-aminoimidazole and 2-aminobenzimidazole. These mono and bicyclic heterocyles may be considered bioisosteres of 2-aminothiazole.
Temple University--Theses
Kim, Young-Woo. "Novel 2-substituted isoflavones a privileged structure approach to new agents for hormone-dependent breast cancer /." Columbus, Ohio : Ohio State University, 2003. http://rave.ohiolink.edu/etdc/view?acc%5Fnum=osu1061576906.
Full textTitle from first page of PDF file. Document formatted into pages; contains xxiii, 249 p. : ill. Advisor: Robert W. Brueggemeier, College of Pharmacy. Includes bibliographical references (p. 234-249).
Valot, Gaëlle. "Extending the diversity of privileged natural product motifs : Synthesis of a library of resorcylic acid lactones and studies towards the guaianes and pseudoguaianes." Strasbourg, 2011. https://publication-theses.unistra.fr/public/theses_doctorat/2011/VALOT_Gaelle_2011.pdf.
Full textThe resorcylic acid lactones bearing a cis-enone functionality proved to be potent and irreversible inhibitors of protein kinases, a class of enzymes implicated in every transduction pathways whose dysfunction is at the origin of pathologies ranging from oncology to inflammation and neurodegenerative diseases. Attracted by their important biological activity, our laboratory developed a synthetic pathway to these pharmacophores, based on the fluorous tags technology. The first part of my thesis consisted in applying this synthesis to the elaboration of a library of 51 macrocycles. This library allowed to identify two modifications as increasing the biological activity : the introduction of an extra carbon in the macrocycle and of a hydroxyl group in β position of the diol. The second part of my thesis consisted in developing a general synthetic pathway to access various members of another class of potent irreversible inhibitors : the sesquiterpene lactones. These compounds exibit a wide spectrum of biological activity including cytotoxic, anti-tumor and anti-inflammatory properties. Unfortunately most of the targets and mode of action associated with these properties have not been identified yet. The synthetic pathway developed, based on a simple central bicyclic intermediate achievable in 13 steps (with the key step being a domino enyne metathesis) and inspired by the biogenesis, should allow the development of "tool compounds" to address these questions. This synthesis has been applied in particular to the preparation of the natural products geigerin and 6-deoxy-geigerin
Patterson, David Josh. "A Tale of Two Carlos: An Examination of the Ongoing Battle Between the Marginalized and the Privileged as Exemplified by Carlo Goldoni and Carlo Gozzi During the 18th Century." DigitalCommons@USU, 2011. https://digitalcommons.usu.edu/etd/1006.
Full textWright, Angela J. "The asymmetric synthesis of B-amino acid derived privileged structures." Thesis, University of Oxford, 2004. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.534191.
Full textBispo, Júnior Walfrido. "Estudo da atividade antinoceptiva e anti-inflamatoria protótipos de fármacos." Universidade Federal de Alagoas, 2013. http://www.repositorio.ufal.br/handle/riufal/3551.
Full textNeste trabalho foi realizado a avaliação da atividade antinocieptiva e anti-inflamatória de duas séries de derivados N-acilidrazonas (NAH) racionalmente planejadas e sintetizados pelo LASSBio® da UFRJ. A primeira serie é formada de 4 compostos, sendo 2 complexos metálicos gerados a partir da coordenação dos protótipos LASSBio-466 e LASSBio-1064 e 2 protótipos LASSBio-466 e LASSBio-1064. A segunda série formada por 8 derivados, desenhados como análogos estruturais do piroxicam. Foram realizados modelos funcionais de nocicepção química (contorção abdominal induzida por ácido acético 0,1N, ensaio de formalina), nocicepção térmica (ensaio da placa quente), ensaio de migração celular (peritonite induzido por zymosan A e/ou induzido por carragenina) ensaio de avaliação de inibição da COX-1/COX-2. Todos os compostos e padrões foram administrados 40 min antes do início ensaio (vo) na dose de 100 μmol/kg. Na primeira série, a constrição animal induzida por ácido acético foi inibida por todos os compostos estudados, destacando-se o [Zn(LASSBio-466)H2O]2 e H2LASSBio-1064 que inibiram (p˂0,01) em 82,7% (p˂0,01) e 81,3% (p˂0,01) o numero de contorções, enquanto o fármaco-padrão (dipirona) inibiu em 77,7% (p˂0,01). Na primeira fase do ensaio de formalina o H2LASSBio-1064 e H2LASSBio-466 reduziram o tempo de latência de lambida em 53,1% (p˂0,05) e 46,5% p˂0,01), respectivamente. Já na segunda fase do ensaio os compostos H2LASSBio-1064 e [Zn(LASSBio-466) H2O]2 reduziram o tempo de latência de lambida em em 48,5% (p˂0,05) e 37,3% (p˂0,05), respectivamente. Todos os compostos mostraram níveis de inibição da peritonite induzida por zymosan comparáveis ou superiores à indometacina (fármaco padrão). Na segunda série, os compostos mostraram-se ativas no ensaio de contorções abdominais induzida por acido acético destacando-se o LASSBio-1638, LASSBio-1639 e LASSBio-1604 que inibiram as contorções abdmoniais em 84,0% (p˂0,01), 82,7% (p˂0,01) e 90,4% (p˂0,01), respectivamente, ao passo que o piroxicam (fármaco padrão) inibiu em 95,4% (p˂0,01). No teste de formalina, apenas LASSBio-1617 inibiu significativamente a atividade nociceptiva na primeira fase em 58,2% (p <0,01). Na segunda fase o LASSBio-1637, LASSBio-1638 inibiram a atividade nociceptiva em 60,0% (p <0,05), e 54,2% (p <0,05), respectivamente, e o piroxicam inibiu em 53,9% (p <0,01). Em modelos de inflamação aguda, os compostos apresentaram atividade inibitória sobre a migração celular semelhante ou maior que o piroxicam. No ensaio de peritonite aguda induzida por carragenina os compostos LASSBio-1604, LASSBio-1637, LASSBio-1638 e LASSBio-1639 inibiram a migração celular em 74,2% (p˂0,01), 73,2% (p˂0,01), 77,6% (p˂0,01) e 81,8% (p˂0,01), respectivamente, ao passo que o piroxicam inibiu 25,5% (p˂0,01). Os compostos LASSBio-1637, LASSBio-1638 e LASSBio-1639 destacaram-se no ensaio de peritonite aguda induzida por zymosan A, inibindo a migração celular em 78,6% (p˂0,01), 81,2% (p˂0,01) e 82,7% (p˂0,01), mostrando-se, nesse ensaio, mais ativos que o piroxicam (57,3%). LASSBio-1604 e LASSBio-1617 inibiram a enzima COX in vitro, apresentando, respectivamente, valores de CI50 de 0,22 M e 0,28 M para inibição de COX-1 e 0,24 M e 0,26 M para inibição de COX-2. Os resultados da avaliação farmacológica sugerem que, na primeira série, a coordenação do zinco (II) é uma boa estratégia para melhorar a atividade antinociceptiva do composto H2LASSBio-466 associada a dor inflamatória, e na segunda série, que todos compostos apresentam atividades antinociceptiva e anti-inflamatória semelhantes ou superiores ao piroxicam.
Balakrishnan, Shalini. "Development of novel switchable motifs and new strategies to build functionally privileged structures." Access to citation, abstract and download form provided by ProQuest Information and Learning Company; downloadable PDF file, 220 p, 2007. http://proquest.umi.com/pqdweb?did=1464120641&sid=2&Fmt=2&clientId=8331&RQT=309&VName=PQD.
Full textDi, Martino Rita Maria Concetta <1987>. "Naturally Inspired Privileged Structures in Drug Discovery: Multifunctional Compounds for Alzheimer's Disease Treatment." Doctoral thesis, Alma Mater Studiorum - Università di Bologna, 2016. http://amsdottorato.unibo.it/7582/.
Full textBooks on the topic "Privileged structure"
Yet, Larry. Privileged Structures in Drug Discovery. Hoboken, NJ, USA: John Wiley & Sons, Inc., 2018. http://dx.doi.org/10.1002/9781118686263.
Full textOzer, Mark N. Massachusetts Avenue in the Gilded Age: Palaces & privilege. Charleston, SC: History Press, 2010.
Find full textLand and privilege in Byzantium: The institution of pronoia. Cambridge: Cambridge University Press, 2012.
Find full textMassachusetts Avenue in the Gilded Age: Palaces and privilege. Charleston, SC: History Press, 2010.
Find full textBazzoni, Giancarlo. Il caso Cavalli e le origini di Porto Corsini: 1671-1802 : nobiltà e privilegi a Ravenna nel secolo XVII. Ravenna: Fondazione Cassa di risparmio di Ravenna, 1999.
Find full textPrivilege, power, and place: The geography of the American upper class. Lanham, Md: Rowman & Littlefield Publishers, 1995.
Find full textVilla Piatti e il feudo di Pigozzo Veronese: Anno 1073 : il Privilegio di Beatrice e Matilde di Canossa a favore dell'Abbazia di San Zeno Maggiore. Verona: QuiEdit, 2009.
Find full textCicero, Patrizia Lo. Villa Piatti e il feudo di Pigozzo Veronese: Anno 1073 : il Privilegio di Beatrice e Matilde di Canossa a favore dell'Abbazia di San Zeno Maggiore. Verona: QuiEdit, 2009.
Find full textKubrin, Charis E., and Gregory D. Squires. Privileged Places: Race, Residence, And the Structure of Opportunity. Lynne Rienner Publishers, 2006.
Find full textSpinley, B. M. The Deprived and the Privileged: International Library of Sociology I: Class, Race and Social Structure (International Library of Sociology). Routledge, 2003.
Find full textBook chapters on the topic "Privileged structure"
Gossage, Robert A. "Pincer Complexes of Lithium, Sodium, Magnesium and Related Metals: A Discussion of Solution and Solid-State Aggregated Structure and Reactivity." In The Privileged Pincer-Metal Platform: Coordination Chemistry & Applications, 17–44. Cham: Springer International Publishing, 2015. http://dx.doi.org/10.1007/3418_2015_119.
Full textBywater, R. P. "Privileged Structures in GPCRs." In Ernst Schering Foundation Symposium Proceedings, 75–92. Berlin, Heidelberg: Springer Berlin Heidelberg, 2007. http://dx.doi.org/10.1007/2789_2006_004.
Full textFallani, Andrea. "La rielaborazione dei mitemi orfici in Microcosmi. Tra vulgata classica e favola indiana." In Biblioteca di Studi di Filologia Moderna, 355–71. Florence: Firenze University Press, 2021. http://dx.doi.org/10.36253/978-88-5518-338-3.27.
Full textKubinyi, Hugo. "Privileged Structures and Analogue-Based Drug Discovery." In Analogue-based Drug Discovery, 53–68. Weinheim, FRG: Wiley-VCH Verlag GmbH & Co. KGaA, 2006. http://dx.doi.org/10.1002/3527608001.ch3.
Full textMohatt, Nathaniel Vincent, and Dennis Mohatt. "Rural Prejudice-Urban Bias: The Stories and Structures That Oppress Rural Communities." In Prejudice, Stigma, Privilege, and Oppression, 413–25. Cham: Springer International Publishing, 2020. http://dx.doi.org/10.1007/978-3-030-35517-3_23.
Full textKallio, Alexis Anja. "Doing Dirty Work: Listening for Ignorance Among the Ruins of Reflexivity in Music Education Research." In The Politics of Diversity in Music Education, 53–67. Cham: Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-65617-1_5.
Full textSun, Shiding, Chunhua Zhang, and Yingjie Tian. "A New Method for Structured Learning with Privileged Information." In Lecture Notes in Computer Science, 453–61. Cham: Springer International Publishing, 2018. http://dx.doi.org/10.1007/978-3-319-93701-4_35.
Full textMeutermans, Wim D. F., Simon W. Golding, Marc R. Campitelli, Douglas A. Horton, Gregory T. Bourne, and Mark L. Smythe. "Privilege Structures: New Strategies for the Synthesis of Cyclic Tetrapeptides." In Peptides: The Wave of the Future, 122–24. Dordrecht: Springer Netherlands, 2001. http://dx.doi.org/10.1007/978-94-010-0464-0_54.
Full textBenn, Emma. "Power and Privilege: Reshaping the Opportunity Structure for Equitable Leadership in Statistics and Data Science." In Leadership in Statistics and Data Science, 19–28. Cham: Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-60060-0_2.
Full textFibbi, Rosita, Arnfinn H. Midtbøen, and Patrick Simon. "Theories of Discrimination." In IMISCOE Research Series, 21–41. Cham: Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-67281-2_3.
Full textConference papers on the topic "Privileged structure"
Podlesskaya, V. I. ""A TOT PEROVSKOJ NE DAL VSLAST' POSPAT'": PROSODY AND GRAMMAR OF ANAPHORIC TOT THROUGH THE LENS OF CORPUS DATA." In International Conference on Computational Linguistics and Intellectual Technologies "Dialogue". Russian State University for the Humanities, 2020. http://dx.doi.org/10.28995/2075-7182-2020-19-628-643.
Full textPesant, Gilles. "From Support Propagation to Belief Propagation in Constraint Programming (Extended Abstract)." In Twenty-Ninth International Joint Conference on Artificial Intelligence and Seventeenth Pacific Rim International Conference on Artificial Intelligence {IJCAI-PRICAI-20}. California: International Joint Conferences on Artificial Intelligence Organization, 2020. http://dx.doi.org/10.24963/ijcai.2020/715.
Full textZhu, Wenfang, Xiuyi Jia, and Weiwei Li. "Privileged label enhancement with multi-label learning." In Twenty-Ninth International Joint Conference on Artificial Intelligence and Seventeenth Pacific Rim International Conference on Artificial Intelligence {IJCAI-PRICAI-20}. California: International Joint Conferences on Artificial Intelligence Organization, 2020. http://dx.doi.org/10.24963/ijcai.2020/329.
Full textZunno, Antonio. "La fortezza e il suo giardino: uno sguardo dal mare." In FORTMED2020 - Defensive Architecture of the Mediterranean. Valencia: Universitat Politàcnica de València, 2020. http://dx.doi.org/10.4995/fortmed2020.2020.11368.
Full textFang, Chien, and Li Nianzhong. "Urban Design Practice in "Instant New Towns"." In 1995 ACSA International Conference. ACSA Press, 1995. http://dx.doi.org/10.35483/acsa.intl.1995.46.
Full textMeneguele, Bruno, Keiko Fonseca, and Marcelo Rosa. "Secure Kernel Execution with Intel SGX." In Simpósio Brasileiro de Engenharia de Sistemas Computacionais. Sociedade Brasileira de Computação, 2020. http://dx.doi.org/10.5753/sbesc_estendido.2020.13108.
Full textJoshi, Alhad, Binu Panicker, and Shashidhar Lakshminarayana. "Product Performance Validation Life Cycle Management." In ASME 2009 International Design Engineering Technical Conferences and Computers and Information in Engineering Conference. ASMEDC, 2009. http://dx.doi.org/10.1115/detc2009-86088.
Full textde Fraguier, Eric, Antoine Guelfi, Luc Vanhoenacker, Olivier Rousselot, Michel Béolet, and Valérie Bellens. "The European Utility Requirements (EUR): A Great Achievement and Still on its Way." In 2013 21st International Conference on Nuclear Engineering. American Society of Mechanical Engineers, 2013. http://dx.doi.org/10.1115/icone21-16914.
Full textĐurić, Stefan, and Bojana Lalatović. "SOLIDARITY CHECK IN TIMES OF COVID-19. ANALYSIS OF THE EU APPROACH TOWARDS ITS CLOSEST NEIGHBOURS WITH A SPECIAL FOCUS ON MONTENEGRO." In EU 2021 – The future of the EU in and after the pandemic. Faculty of Law, Josip Juraj Strossmayer University of Osijek, 2021. http://dx.doi.org/10.25234/eclic/18303.
Full textVe´tel, Je´roˆme, Andre´ Garon, and Dominique Pelletier. "Analysis of Complex Flows From Experimental Data and Numerical Experiments." In ASME 2010 3rd Joint US-European Fluids Engineering Summer Meeting collocated with 8th International Conference on Nanochannels, Microchannels, and Minichannels. ASMEDC, 2010. http://dx.doi.org/10.1115/fedsm-icnmm2010-30033.
Full text